Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
Open Access
- 5 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Addiction Science & Clinical Practice
- Vol. 16 (1), 1-11
- https://doi.org/10.1186/s13722-021-00253-7
Abstract
Background: Office-Based Opioid Treatment (OBOT) is a delivery model which seeks to make medications for opioid use disorder (MOUD), particularly buprenorphine, widely available in general medical clinics and offices. Despite evidence supporting its effectiveness and cost-effectiveness, uptake of the OBOT model has been relatively slow. One important barrier to faster diffusion of OBOT may be the financial challenges facing clinics that could adopt it. Methods: We review key features and variants of the OBOT model, then discuss different approaches that have been used to fund it, and the findings from previous economic analyses of OBOT’s impact on organizational finances. We conclude by discussing the implications of these analyses for the financial sustainability of the OBOT delivery model. Results: Like other novel services, OBOT poses challenges for providers due to its reliance on services which are ‘non-billable’ in a fee-for-service environment. A variety of approaches exist for covering the non-billable costs, but which approaches are feasible depends on local payer policies. The scale of the challenges varies with clinic size, organizational affiliations and the policies of the state where the clinic operates. Small clinics in a purely fee-for-service environment may be particularly challenged in pursuing OBOT, given the need to fund a dedicated staff and extra administrative work. The current pandemic may pose both opportunities and challenges for the sustainability of OBOT, with expanded access to telemedicine, but also uncertainty about the durability of the expansion. Conclusion: The reimbursement environment for OBOT delivery varies widely around the US, and is evolving as Medicare (and possibly other payers) introduce alternative payment approaches. Clinics considering adoption of OBOT are well advised to thoroughly investigate these issues as they make their decision. In addition, payers will need to rethink how they pay for OBOT to make it sustainable.Keywords
Funding Information
- National Institute on Drug Abuse (P30 DA035772)
This publication has 43 references indexed in Scilit:
- Medication-Assisted Therapies — Tackling the Opioid-Overdose EpidemicThe New England Journal of Medicine, 2014
- Barriers to Primary Care Physicians Prescribing BuprenorphineAnnals of Family Medicine, 2014
- Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disordersJournal of Substance Abuse Treatment, 2013
- Perceived unmet need for alcohol and drug use treatments and future use of services: Results from a longitudinal studyDrug and Alcohol Dependence, 2013
- Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adoptersJournal of Opioid Management, 2012
- Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome ThemCurrent Psychiatry Reports, 2011
- Collaborative Care of Opioid-Addicted Patients in Primary Care Using BuprenorphineJAMA Internal Medicine, 2011
- Adoption and Implementation of Medications in Addiction Treatment ProgramsJournal of Addiction Medicine, 2011
- Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 YearsThe American Journal on Addictions, 2008
- Aligning Incentives in the Treatment of Depression in Primary Care With Evidence-Based PracticePsychiatric Services, 2003